VKTX Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $4.9M.
Where they traded
Last open-market purchase: March 10, 2026 , by Aubuchon Neil William .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Lian Brian | President & CEO | Sell | 148,517 | $33.32 | $4.9M | 2,572,441 −5.5% of holding | |
| ZANTE GREG | Chief Financial Officer | Sell | 21,217 | $33.47 | $710.1K | 212,204 −9.1% of holding | |
| Mancini Marianna | Chief Operating Officer | Sell | 18,217 | $33.47 | $609.6K | 422,760 −4.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.